Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

C5aR and C3aR antagonists each inhibit diet-induced obesity, metabolic dysfunction, and adipocyte and macrophage signaling.

Lim J, Iyer A, Suen JY, Seow V, Reid RC, Brown L, Fairlie DP.

FASEB J. 2013 Feb;27(2):822-31. doi: 10.1096/fj.12-220582. Epub 2012 Nov 1.

PMID:
23118029
2.

Pharmacological targeting of anaphylatoxin receptors during the effector phase of allergic asthma suppresses airway hyperresponsiveness and airway inflammation.

Baelder R, Fuchs B, Bautsch W, Zwirner J, Köhl J, Hoymann HG, Glaab T, Erpenbeck V, Krug N, Braun A.

J Immunol. 2005 Jan 15;174(2):783-9.

3.

Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models.

Ames RS, Lee D, Foley JJ, Jurewicz AJ, Tornetta MA, Bautsch W, Settmacher B, Klos A, Erhard KF, Cousins RD, Sulpizio AC, Hieble JP, McCafferty G, Ward KW, Adams JL, Bondinell WE, Underwood DC, Osborn RR, Badger AM, Sarau HM.

J Immunol. 2001 May 15;166(10):6341-8.

4.

C5L2 and C5aR interaction in adipocytes and macrophages: insights into adipoimmunology.

Poursharifi P, Lapointe M, Pétrin D, Devost D, Gauvreau D, Hébert TE, Cianflone K.

Cell Signal. 2013 Apr;25(4):910-8. doi: 10.1016/j.cellsig.2012.12.010. Epub 2012 Dec 23.

PMID:
23268185
5.

The C3a anaphylatoxin receptor is a key mediator of insulin resistance and functions by modulating adipose tissue macrophage infiltration and activation.

Mamane Y, Chung Chan C, Lavallee G, Morin N, Xu LJ, Huang J, Gordon R, Thomas W, Lamb J, Schadt EE, Kennedy BP, Mancini JA.

Diabetes. 2009 Sep;58(9):2006-17. doi: 10.2337/db09-0323. Epub 2009 Jul 6.

6.

The complement anaphylatoxin C5a receptor contributes to obese adipose tissue inflammation and insulin resistance.

Phieler J, Chung KJ, Chatzigeorgiou A, Klotzsche-von Ameln A, Garcia-Martin R, Sprott D, Moisidou M, Tzanavari T, Ludwig B, Baraban E, Ehrhart-Bornstein M, Bornstein SR, Mziaut H, Solimena M, Karalis KP, Economopoulou M, Lambris JD, Chavakis T.

J Immunol. 2013 Oct 15;191(8):4367-74. doi: 10.4049/jimmunol.1300038. Epub 2013 Sep 16.

7.

C5aR and C5L2 act in concert to balance immunometabolism in adipose tissue.

Poursharifi P, Lapointe M, Fisette A, Lu H, Roy C, Munkonda MN, Fairlie DP, Cianflone K.

Mol Cell Endocrinol. 2014 Jan 25;382(1):325-33. doi: 10.1016/j.mce.2013.10.019. Epub 2013 Oct 25.

PMID:
24397921
8.

Diet-induced obesity, adipose inflammation, and metabolic dysfunction correlating with PAR2 expression are attenuated by PAR2 antagonism.

Lim J, Iyer A, Liu L, Suen JY, Lohman RJ, Seow V, Yau MK, Brown L, Fairlie DP.

FASEB J. 2013 Dec;27(12):4757-67. doi: 10.1096/fj.13-232702. Epub 2013 Aug 20.

9.

C3a and C5a receptor antagonists ameliorate endothelial-myofibroblast transition via the Wnt/β-catenin signaling pathway in diabetic kidney disease.

Li L, Chen L, Zang J, Tang X, Liu Y, Zhang J, Bai L, Yin Q, Lu Y, Cheng J, Fu P, Liu F.

Metabolism. 2015 May;64(5):597-610. doi: 10.1016/j.metabol.2015.01.014. Epub 2015 Jan 29.

PMID:
25682062
10.

Comparative anti-inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury.

Proctor LM, Arumugam TV, Shiels I, Reid RC, Fairlie DP, Taylor SM.

Br J Pharmacol. 2004 Jun;142(4):756-64. Epub 2004 May 24.

11.

Expression of the complement anaphylatoxin C3a and C5a receptors on bronchial epithelial and smooth muscle cells in models of sepsis and asthma.

Drouin SM, Kildsgaard J, Haviland J, Zabner J, Jia HP, McCray PB Jr, Tack BF, Wetsel RA.

J Immunol. 2001 Feb 1;166(3):2025-32.

12.

Mast cell anaphylatoxin receptor expression can enhance IgE-dependent skin inflammation in mice.

Schäfer B, Piliponsky AM, Oka T, Song CH, Gerard NP, Gerard C, Tsai M, Kalesnikoff J, Galli SJ.

J Allergy Clin Immunol. 2013 Feb;131(2):541-8.e1-9. doi: 10.1016/j.jaci.2012.05.009. Epub 2012 Jun 22.

13.

Differential chemoattractant response in adipocytes and macrophages to the action of acylation stimulating protein.

Tom FQ, Gauvreau D, Lapointe M, Lu H, Poursharifi P, Luo XP, Cianflone K.

Eur J Cell Biol. 2013 Feb;92(2):61-9. doi: 10.1016/j.ejcb.2012.10.005. Epub 2012 Dec 14.

PMID:
23245988
14.

Mobilization studies in mice deficient in either C3 or C3a receptor (C3aR) reveal a novel role for complement in retention of hematopoietic stem/progenitor cells in bone marrow.

Ratajczak J, Reca R, Kucia M, Majka M, Allendorf DJ, Baran JT, Janowska-Wieczorek A, Wetsel RA, Ross GD, Ratajczak MZ.

Blood. 2004 Mar 15;103(6):2071-8. Epub 2003 Nov 6.

15.

Expression of receptors for complement anaphylatoxins C3a and C5a following permanent focal cerebral ischemia in the mouse.

Van Beek J, Bernaudin M, Petit E, Gasque P, Nouvelot A, MacKenzie ET, Fontaine M.

Exp Neurol. 2000 Jan;161(1):373-82.

PMID:
10683302
16.

Derivation of ligands for the complement C3a receptor from the C-terminus of C5a.

Halai R, Bellows-Peterson ML, Branchett W, Smadbeck J, Kieslich CA, Croker DE, Cooper MA, Morikis D, Woodruff TM, Floudas CA, Monk PN.

Eur J Pharmacol. 2014 Dec 15;745:176-81. doi: 10.1016/j.ejphar.2014.10.041. Epub 2014 Oct 30.

17.

Synthetic small-molecule complement inhibitors.

Holland MC, Morikis D, Lambris JD.

Curr Opin Investig Drugs. 2004 Nov;5(11):1164-73. Review.

PMID:
15573867
18.

Inhibition of inflammation and fibrosis by a complement C5a receptor antagonist in DOCA-salt hypertensive rats.

Iyer A, Woodruff TM, Wu MC, Stylianou C, Reid RC, Fairlie DP, Taylor SM, Brown L.

J Cardiovasc Pharmacol. 2011 Nov;58(5):479-86. doi: 10.1097/FJC.0b013e31822a7a09.

PMID:
21753735
19.
20.

The C3a receptor antagonist SB 290157 has agonist activity.

Mathieu MC, Sawyer N, Greig GM, Hamel M, Kargman S, Ducharme Y, Lau CK, Friesen RW, O'Neill GP, Gervais FG, Therien AG.

Immunol Lett. 2005 Sep 15;100(2):139-45. Epub 2005 Mar 25.

PMID:
16154494

Supplemental Content

Support Center